These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2903567)

  • 1. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes.
    Beal MF; Clevens RA; Mazurek MF
    Synapse; 1988; 2(4):463-7. PubMed ID: 2903567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Svendsen CN; Bird ED; Martin JB
    Ann Neurol; 1986 Oct; 20(4):489-95. PubMed ID: 3789664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease.
    Beal MF; Mazurek MF; Ellison DW; Swartz KJ; McGarvey U; Bird ED; Martin JB
    Ann Neurol; 1988 Jun; 23(6):562-9. PubMed ID: 2900622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases.
    Perry RH; Perry EK; Smith CJ; Xuereb JH; Irving D; Whitford CA; Candy JM; Cross AJ
    J Neural Transm Suppl; 1987; 24():131-6. PubMed ID: 2824687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease.
    Davies CA; Morroll DR; Prinja D; Mann DM; Gibbs A
    J Neurol Sci; 1990 Apr; 96(1):59-73. PubMed ID: 1972185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes.
    Beal MF; Mazurek MF; Martin JB
    Brain Res; 1986 Nov; 397(2):386-8. PubMed ID: 3801878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1988 Feb; 23(2):105-14. PubMed ID: 2897822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex.
    Gabriel SM; Bierer LM; Harotunian V; Purohit DP; Perl DP; Davis KL
    Neurosci Lett; 1993 May; 155(1):116-20. PubMed ID: 8103205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
    Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
    Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer's disease striatum.
    Beal MF; Mazurek MF; McKee MA
    Neurosci Lett; 1987 Aug; 79(1-2):201-6. PubMed ID: 2890123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropeptides in neurological disease.
    Beal MF; Martin JB
    Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?
    Papapetropoulos S; Lieberman A; Gonzalez J; Mash DC
    Acta Neurol Scand; 2005 Jun; 111(6):353-9. PubMed ID: 15876335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid beta-peptide and the dementia of Parkinson's disease.
    Jendroska K; Lees AJ; Poewe W; Daniel SE
    Mov Disord; 1996 Nov; 11(6):647-53. PubMed ID: 8914090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropathological substrates of Alzheimer's disease and Parkinson's disease.
    Jellinger K
    J Neural Transm Suppl; 1987; 24():109-29. PubMed ID: 3316494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia.
    Beal MF; Svendsen CN; Bird ED; Martin JB
    Neurochem Pathol; 1987 Jun; 6(3):169-76. PubMed ID: 2888067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases.
    Whitford C; Candy J; Edwardson J; Perry R
    J Neurol Sci; 1988 Aug; 86(1):13-8. PubMed ID: 2902199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical muscarinic receptors in demented patients with Alzheimer's disease or Parkinson's disease.
    Lange KW; Wells FR; Rossor MN; Jenner P; Marsden CD
    Br J Pharmacol; 1989 Dec; 98 Suppl():817P. PubMed ID: 2611524
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
    Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies.
    Mosimann UP; Müri RM; Burn DJ; Felblinger J; O'Brien JT; McKeith IG
    Brain; 2005 Jun; 128(Pt 6):1267-76. PubMed ID: 15774501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.